<DOC>
	<DOC>NCT02438709</DOC>
	<brief_summary>The purpose of this study is to determine whether COX-2 inhibitor is effective in the treatment of primary hypertrophic osteoarthropathy</brief_summary>
	<brief_title>Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy</brief_title>
	<detailed_description>Patients with primary hypertrophic osteoarthropathy(PHO) were diagnosed based on clinical manifestations and symptoms. PHO patients were treated with COX-2 inhibitor after signing informed consent. The extend of alleviation, the change of the markers on prostaglandin E metabolic pathway and the adverse event on different time points were recorded to identify the efficacy and safety.</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Osteoarthropathy, Primary Hypertrophic</mesh_term>
	<mesh_term>Osteoarthropathy, Secondary Hypertrophic</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<criteria>diagnosed with primary hypertrophic osteoarthropathy clinically over 16 years old no other medication intake informed consent signed below 16 years old active gastric ulcer inflammatory bowel disease New York Heart Association classification（NYHA） II to IV liver or renal failure allergic to nonsteroid antiinflammatory drugs not willing to participate</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>